Skip to: Curated Story Group 1
healthcarebusinessreview

Advertise

with us

    • US
    • EUROPE
    • APAC
    • CANADA
  • Home
  • Sections
    Business Process Outsourcing
    Compliance & Risk Management
    Consulting Service
    Facility Management Services
    Financial Services
    Healthcare BPO
    Healthcare Digital Marketing
    Healthcare Education
    Healthcare Procurement
    Healthcare Security
    Healthcare Staffing
    Long-Term Care Pharmacy Services
    Medical Billing
    Medical Transportation
    Practice Management Service
    Real Estate Services
    Supply Chain
    Therapy Services
  • Contributors
  • News
  • Vendors
  • Conferences
  • Awards
Welcome back to this new edition of Healthcare Business Review !!!✖
Sign In

Subscribe to our Weekly Newsletter to get latest updates to your inbox
3 July - 2022Hovione TechnologyDry Power Inhalerswww.hovionetechnology.cominfo@hovionetechnology.comPowdAirCAPSULE BASEDLARGE DOSE 8 x 50 mgBLISTER BASEDDISPOSABLE 2 x 50 mg8ShotPapillonTwinCapsPrecision built,few partsA ordable,at global scaleE ective, market provenEasy to use, attractiveInnovative, patents to 2038Innovative, eective and globally a ordable DPIsHovione Technology, a specialist in innovative inhalation device technology, has developed a complete portfolio of effective and globally affordable dry powder inhalers ­ disposable, capsule-based, blister-based and large dose DPIs. Featuring easy-to-use, attractive designs that are precision built from few plastic parts for maximum affordability and minimum environmental impact, all our inhalers are available for development, supply and licensing. With over 20 years of expertise developing innovative inhalers, our team was behind the first approved disposable inhaler, the TwinCaps DPI, marketed in Japan for influenza, and the new market approved capsule DPI for Asthma and COPD management, the PowdAir Plus DPI. Millions of patients are being treated every year with Hovione Technology's inhalers.CMYCMMYCYCMYKAF_210X297_Hovione_Anuncio_MedTech Outlook.pdf 1 16/03/2021 13:32
< Page 2 | Page 4 >